A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

Launched by ABBVIE ·

Keywords

ClinConnect Summary

This clinical trial is studying a new oral medicine called emraclidine to see how safe it is, how it affects symptoms, and how it moves through the body in adults with schizophrenia. Schizophrenia is a serious mental health condition that affects how a person thinks, feels, and perceives the world. The study will compare emraclidine to a placebo (a pill with no active medicine) to understand its effects better.

Adults with schizophrenia may be eligible to join if they meet certain health criteria. Participants will be divided into two groups: one group will take different doses of emraclidine or placebo for about 2 to 3 weeks, and the other group will take the medicine or placebo for up to 6 weeks. During the study, participants will visit the clinic regularly for medical check-ups, blood tests, and to report any side effects. After finishing the treatment, they will be followed for 30 more days to monitor their health. It’s important to know that joining this trial may require more time and effort than usual care, but it helps researchers learn if emraclidine could be a helpful treatment for schizophrenia in the future.

Gender

ALL

Eligibility criteria